Recent research highlights a significant gap in the utilization of next-generation sequencing (NGS) for patients diagnosed with advanced cancer. A retrospective cohort study revealed that nearly half of those diagnosed over a five-year span did not receive this crucial testing.
While there has been progress in testing rates over time, disparities persist. Factors such as socioeconomic status, race, ethnicity, and insurance coverage have been identified as barriers to timely access to NGS.
These findings emphasize the urgent need for increased awareness about the value of NGS. Researchers advocate for the development of strategies that promote equitable access to testing for all patients.
The Importance of Early Testing
Dr. Umang Swami, a genitourinary medical oncologist at the University of Utah’s Huntsman Cancer Institute, stresses the necessity of genomic testing at the patient’s first clinical visit. He argues that early NGS can significantly expand treatment options. “NGS testing should not be delayed until standard therapies have failed,” he noted. This testing is integral to managing most cancers, allowing for the selection of targeted therapies and immunotherapies based on genomic findings.
Underutilization of NGS in Oncology
Prior studies have shown that NGS is often underused in oncology settings. In a recent study led by Swami, it was found that most patients with metastatic prostate or urothelial cancers did not undergo NGS, despite the existence of approved targeted therapies for these conditions. This underutilization highlights the need for systemic changes in how cancer care is approached.
A previous presentation at the ASCO Annual Meeting revealed that many patients with common cancers received their NGS results too late, with a quarter of them testing within three months of their death. This situation calls for an urgent examination of the testing timelines across various tumor types.
Study Overview and Findings
To better understand the trends and disparities in NGS testing, researchers analyzed data from the Flatiron Health Research Database, which included deidentified health records from 280 cancer clinics across the U.S. Their study encompassed 63,294 patients diagnosed with advanced or metastatic cancers between 2018 and 2022.
The cohort primarily consisted of individuals with non-small cell lung cancer (NSCLC), colorectal cancer, breast cancer, pancreatic cancer, and prostate cancer. Recommended guidelines advocate for NGS in all these cancer types to inform treatment decisions.
The study revealed that slightly more than half (58.7%) of the patients underwent NGS testing. Testing rates were highest for colorectal cancer (67%) and NSCLC (65.9%), while breast cancer (40.3%) and prostate cancer (49.8%) lagged behind.
Timeliness of Testing by Tumor Type
The time taken from diagnosis to NGS testing varied significantly among tumor types. Patients with NSCLC received testing the fastest, with a median time of less than a month, while those with prostate cancer faced delays of nearly a year. By the one-year mark post-diagnosis, testing rates were notably higher in patients with NSCLC, colorectal cancer, and pancreatic cancer compared to their counterparts with breast or prostate cancer.
Encouragingly, testing rates have improved over time. Patients diagnosed in 2022 showed a marked increase in testing within the first year compared to those diagnosed in 2018. For breast cancer, testing rates tripled, while rates for prostate cancer more than tripled as well. This upward trend is a positive development in the landscape of cancer care.
Factors Influencing Testing Disparities
The study identified several factors influencing the time to NGS testing. Issues such as lower referral rates for testing and historical mistrust in the healthcare system were noted, particularly among racial and ethnic minorities. Additionally, high costs and inconsistent insurance coverage hindered access for individuals on Medicaid or Medicare and those from lower socioeconomic backgrounds.
These findings highlight the need for enhanced clinician awareness regarding testing guidelines and the preferences of patients. There is a critical need for efforts aimed at ensuring equitable access to standard diagnostic procedures for all individuals.
Future Outlook for NGS in Oncology
Dr. Swami remains optimistic about the future of NGS in oncology. He believes that testing rates could reach as high as 90% in the near future. The decreasing costs of NGS, coupled with increased education for oncologists and care teams, are expected to drive further improvements in testing rates.
As awareness grows among patients and caregivers, more individuals will likely seek and receive genomic testing. This evolution promises to unlock new avenues for effective cancer treatment, transforming patient care in profound ways.
In summary, while challenges remain in the implementation of next-generation sequencing for advanced cancer, the progress made thus far is encouraging. Addressing disparities and expanding access could significantly enhance patient outcomes and treatment options in the years to come.
Key Takeaways
- Nearly 50% of advanced cancer patients did not receive NGS testing in a recent study.
- Socioeconomic factors and insurance coverage significantly impact access to testing.
-
Early NGS testing is crucial for expanding treatment options for cancer patients.
-
Testing rates have improved over the years, but disparities persist across different cancer types.
-
Increased clinician education and awareness are essential for promoting equitable access to genomic testing.
Read more → www.healio.com